All In Biotech

Drug Trial Radar · NCT05678998

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients With Advanced or Metastatic Solid Tumors or Lymphoma

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Dec 6, 2022

Primary completion

Dec 23, 2024

Study completion Feb 5, 2025

Sponsor

Lead sponsor
Werewolf Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.

Conditions

  • Advanced or Metastatic Solid Tumors
  • Non-Hodgkin Lymphoma

Interventions

  • WTX-330Drug

    Investigation Product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs)Time frame: 4 weeks
  2. Incidence of Treatment Emergent Adverse EventsTime frame: 24 months
  3. Incidence of Changes in Clinical Laboratory AbnormalitiesTime frame: 24 months
  4. Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas)Time frame: 24 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdale, Arizona

  • Emory Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • Mass General Hospital

    Boston, Massachusetts

  • Facility Name: Roswell Park Comprehensive Cancer Care

    Buffalo, New York

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • NEXT Oncology

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.